Opthea Limited (OPT)
All research reports and stock updates for Opthea Limited.
Research Reports
Health Care
Opthea Limited (OPT)
Funding the science
Opthea’s Phase 3 trial for its wAMD treatment (OPT-302) is well underway. The science is working, and now OPT has matched that success by securing funding that will not only get the product ready for commercialisation but keep control of the process.
Health Care
Opthea Limited (OPT)
Trials take time
Opthea’s Phase 3 trial of its promising treatment for wet Age-related Macular Degeneration (wAMD) is nearing its halfway mark, as other competitors’ trials begin to fall away.